Tanja Langsenlehner

List of Publications by Year
in descending order

33	598	516710 16	610901 24
papers	citations	h-index	g-index

33	33	33	1095
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy. European Journal of Cancer, 2015, 51, 610-619.	2.8	49
2	Association between single nucleotide polymorphisms in the gene for XRCC1 and radiation-induced late toxicity in prostate cancer patients. Radiotherapy and Oncology, 2011, 98, 387-393.	0.6	46
3	Validation of the neutrophil-to-lymphocyte ratio as a prognostic factor in a cohort of European prostate cancer patients. World Journal of Urology, 2015, 33, 1661-1667.	2.2	43
4	Single nucleotide polymorphisms and haplotypes in the gene for vascular endothelial growth factor and risk of prostate cancer. European Journal of Cancer, 2008, 44, 1572-1576.	2.8	39
5	The elevated preoperative derived neutrophil-to-lymphocyte ratio predicts poor clinical outcome in breast cancer patients. Tumor Biology, 2016, 37, 361-368.	1.8	39
6	Long-Term Follow-up of Patients with Pituitary Macroadenomas after Postoperative Radiation Therapy. Strahlentherapie Und Onkologie, 2007, 183, 241-247.	2.0	38
7	An elevated preoperative plasma fibrinogen level is associated with poor disease-specific and overall survival in breast cancer patients. Breast, 2015, 24, 667-672.	2.2	31
8	The association of an elevated plasma fibrinogen level with cancer-specific and overall survival in prostate cancer patients. World Journal of Urology, 2015, 33, 1467-1473.	2.2	27
9	The AST/ALT (De Ritis) Ratio Predicts Survival in Patients with Oral and Oropharyngeal Cancer. Diagnostics, 2020, 10, 973.	2.6	26
10	Evaluation of the platelet-to-lymphocyte ratio as a prognostic indicator in a European cohort of patients with prostate cancer treated with radiotherapy. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 201.e9-201.e16.	1.6	25
11	The Glu228Ala polymorphism in the ligand binding domain of death receptor 4 is associated with increased risk for prostate cancer metastases. Prostate, 2008, 68, 264-268.	2.3	24
12	BCL2Âgenotypes and prostate cancer survival. Strahlentherapie Und Onkologie, 2017, 193, 466-471.	2.0	22
13	Relative telomere length and prostate cancer mortality. Prostate Cancer and Prostatic Diseases, 2018, 21, 579-583.	3.9	19
14	In Vivo Detection of Circulating Tumor Cells in High-Risk Non-Metastatic Prostate Cancer Patients Undergoing Radiotherapy. Cancers, 2019, 11, 933.	3.7	18
15	The Role of Radiation Therapy after Incomplete Resection of Penile Cancer. Strahlentherapie Und Onkologie, 2008, 184, 359-363.	2.0	17
16	Vitamin D and prostate cancer prognosis: a Mendelian randomization study. World Journal of Urology, 2016, 34, 607-611.	2.2	17
17	Catch and Release: rare cell analysis from a functionalised medical wire. Scientific Reports, 2017, 7, 43424.	3.3	17
18	Treatment Results of Radiation Therapy for Muscle-Invasive Bladder Cancer. Strahlentherapie Und Onkologie, 2010, 186, 203-209.	2.0	16

#	Article	IF	Citations
19	Impact of VEGF gene polymorphisms and haplotypes on radiation-induced late toxicity in prostate cancer patients. Strahlentherapie Und Onkologie, 2011, 187, 784-791.	2.0	14
20	The Î±2-isoform of the Na⁺/K⁺-ATPase protects against pathological remodeling and Î²-adrenergic desensitization after myocardial infarction. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 321, H650-H662.	3.2	12
21	The Pre-Treatment C-Reactive Protein Represents a Prognostic Factor in Patients with Oral and Oropharyngeal Cancer Treated with Radiotherapy. Cancers, 2020, 12, 626.	3.7	11
22	The decreased mean platelet volume is associated with poor prognosis in patients with oropharyngeal cancer treated with radiotherapy. Radiation Oncology, 2020, 15, 259.	2.7	10
23	Low spinophilin expression enhances aggressive biological behavior of breast cancer. Oncotarget, 2015, 6, 11191-11202.	1.8	10
24	TRPC4Î± and TRPC4Î² Similarly Affect Neonatal Cardiomyocyte Survival during Chronic GPCR Stimulation. PLoS ONE, 2016, 11, e0168446.	2.5	9
25	The Elevated Pre-Treatment C-Reactive Protein Predicts Poor Prognosis in Patients with Locally Advanced Rectal Cancer Treated with Neo-Adjuvant Radiochemotherapy. Diagnostics, 2020, 10, 780.	2.6	5
26	Haptoglobin polymorphism and prostate cancer mortality. Scientific Reports, 2020, 10, 13117.	3.3	5
27	The Erythropoetin rs1617640 Gene Polymorphism Associates with Hemoglobin Levels, Hematocrit and Red Blood Cell Count in Patients with Peripheral Arterial Disease. Genes, 2020, 11, 1305.	2.4	3
28	Clinical parameters predictive for sphincter-preserving surgery and prognostic outcome in patients with locally advanced low rectal cancer. Radiation Oncology, 2020, 15, 99.	2.7	3
29	The functional polymorphism of erythropoietin gene rs1617640 G>T is not associated with susceptibility and clinical outcome of early-stage breast cancer. Anticancer Research, 2012, 32, 3473-8.	1.1	3
30	Rebuttal to â€œCausal effect of vitamin D on prostate cancer using Mendelian randomization approachâ€. World Journal of Urology, 2016, 34, 615-615.	2.2	0
31	Can Pre-Treatment Inflammatory Parameters Predict the Probability of Sphincter-Preserving Surgery in Patients with Locally Advanced Low-Lying Rectal Cancer?. Diagnostics, 2021, 11, 946.	2.6	0
32	Evaluation of Blood-based Biomarkers for Prediction of Response in Carboplatin-treated Metastatic Castration-resistant Prostate Cancer Patients. In Vivo, 2020, 34, 3631-3638.	1.3	0
33	Reply to Blaustein et al.. American Journal of Physiology - Heart and Circulatory Physiology, 2021, 321, H119-H1120.	3.2	0